Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirepemat - Integrative Research Laboratories

Next Previous
Drug Profile

Pirepemat - Integrative Research Laboratories

Alternative Names: IRL-752

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integrative Research Laboratories
  • Class Antidementias; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Ethers; Fluorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • No development reported Behavioural disorders
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 28 Mar 2025 Updated efficacy data from the phase IIb React-PD trial in Parkinson's disease released by Integrative Research Laboratories
  • 05 Mar 2025 Efficacy and adverse event data from the phase IIb React PD trial in Parkinson's disease released by Integrative Research Laboratories
  • 09 Jan 2025 Integrative Research Laboratories AB completes a phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in Sweden, Spain, France, Poland, Germany and the Netherlands (PO) (NCT05258071) (EudraCT2019-002627-16)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top